Evaluation of the QIAstat-Dx RP2.0 and the BioFire FilmArray RP2.1 for the Rapid Detection of Respiratory Pathogens Including SARS-CoV-2

Abstract

Point-of-care syndromic panels allow for simultaneous and rapid detection of respiratory pathogens from nasopharyngeal swabs. The clinical performance of the QIAstat-Dx Respiratory SARS-CoV-2 panel RP2.0 (QIAstat-Dx RP2.0) and the BioFire FilmArray Respiratory panel RP2.1 (BioFire RP2.1) was evaluated for the detection of SARS-CoV-2 and other common respiratory pathogens. A total of 137 patient samples were retrospectively selected based on emergency department admission, along with 33 SARS-CoV-2 positive samples tested using a WHO laboratory developed test. The limit of detection for SARS-CoV-2 was initially evaluated for both platforms. The QIAstat-Dx RP2.0 detected SARS-CoV-2 at 500 copies/mL and had a positive percent agreement (PPA) of 85%. The BioFire RP2.1 detected SARS-CoV-2 at 50 copies/mL and had a PPA of 97%. Both platforms showed a negative percent agreement of 100% for SARS-CoV-2. Evaluation of analytical specificity from a range of common respiratory targets showed a similar performance between each platform. The QIAstat-Dx RP2.0 had an overall PPA of 82% (67–100%) in clinical samples, with differences in sensitivity depending on the respiratory target. Both platforms can be used to detect acute cases of SARS-CoV-2. While the QIAstat-Dx RP2.0 is suitable for detecting respiratory viruses within a clinical range, it has less analytical and clinical sensitivity for SARS-CoV-2 compared to the BioFire RP2.1.

Respiratory syncytial virus and SARS‐CoV‐2 coinfections in children

“…To determine whether RSV/SARS‐CoV‐2 coinfections occurred and if they were associated with different clinical phenotypes, we identified children with RSV and SARS‐CoV‐2 codetection using the FilmArray Respiratory Panel (BioMérieux), which allows for the simultaneous detection of 22 pathogens including RSV and SARS‐CoV‐2 in nasopharyngeal (NP) samples. 2 We then performed a retrospective chart review and analyzed the clinical characteristics of children that were hospitalized with RSV/SARS‐CoV‐2 codetection as missing data extracted from electronic health records was negligible compared with outpatients. To further ascertain the impact of SARS‐CoV‐2, RSV, or both on clinical presentations, we prospectively identified the NP samples corresponding to those patients and performed individual reverse transcription‐PCRs for SARS‐CoV‐2 and RSV, as the FilmArray panel does not provide viral load information.…”

“…To determine whether RSV/SARS-CoV-2 coinfections occurred and if they were associated with different clinical phenotypes, we identified children with RSV and SARS-CoV-2 codetection using the FilmArray Respiratory Panel (BioMérieux), which allows for the simultaneous detection of 22 pathogens including RSV and SARS-CoV-2 in nasopharyngeal (NP) samples. 2 We then performed a retrospective chart review and analyzed the clinical characteristics of children that were hospitalized with RSV/SARS-CoV-2 codetection as missing data extracted from electronic health records was negligible compared with outpatients.…”

Clinical Evaluation of a Multiplex PCR Assay for Simultaneous Detection of 18 Respiratory Pathogens in Patients with Acute Respiratory Infections

“…In addition, this rapid and high-throughput method for the simultaneous detection of multiple respiratory viruses based on the MPA platform was compared with other multiplex PCR methods to explore the possibility and practicability limitations. In terms of pathogen coverage, some commercial kits, such as QIA stat-SARS (QIAGEN Diagnostics GmbH) [ 25 , 26 ], Fire RP2.1(Bio Fire Diagnostics) [ 27 , 28 ], can detect more than 20 respiratory pathogens, and they share a similar pathogen spectrum with the MPA assay. However, these commercial kits are much more expensive for each reaction than the MPA assay.…”

Evaluation of the Kaira COVID-19/Flu/RSV Detection Kit for detection of SARS-CoV-2, influenza A/B, and respiratory syncytial virus: A comparative study with the PowerChek SARS-CoV-2, influenza A&B, RSV Multiplex Real-time PCR Kit

“…Given the changes in the epidemiology of influenza and RSV, molecular assays to simultaneously detect these viruses and SARS-CoV-2 are urgently needed and should be performed throughout the year. Currently, various molecular assays to simultaneously detect SARS-CoV-2 and other respiratory viruses are commercially available, most of which are sample-to-result rRT-PCR assays [11][12][13][14][15][16][17][18][19][20][21]. Sample-to-result assays such as the RP2.1 and Xpert Xpress SARS-CoV-2/Flu/RSV assays are simple to perform and do not require skilled personnel.…”

“…Furthermore, co-infection of SARS-CoV-2 and other respiratory viruses can occur, albeit at a low rate [9,10]. To address this situation, various molecular assays to simultaneously detect SARS-CoV-2 and other respiratory viruses have been developed and are widely used in clinical settings [11][12][13][14][15][16][17][18][19][20][21].…”